Skin Cancer in Australia 2026
Australia holds the unwanted distinction of being the skin cancer capital of the world. No other country records a higher rate of skin cancer diagnoses, and for Australians, the risk is not theoretical — it is a lived, generational reality. More than 2 in 3 Australians will be diagnosed with some form of skin cancer before the age of 70, a lifetime burden that no other cancer comes close to matching in this country. Skin cancer is not only the most commonly diagnosed cancer in Australia; it accounts for approximately 80% of all new cancer diagnoses each year. The twin drivers behind this extraordinary rate are straightforward: a predominantly fair-skinned population descended largely from Northern European ancestry, and some of the highest levels of ambient UV radiation on Earth, the result of Australia’s proximity to the equator, its abundance of clear-sky days, and the southern hemisphere’s orbital path, which brings Australia closer to the sun during its summer months than equivalent northern hemisphere latitudes experience in theirs.
The 2025 Australian Institute of Health and Welfare (AIHW) Cancer Data in Australia report — the most authoritative and comprehensive dataset available — projects that melanoma alone will account for approximately 17,443 new diagnoses in 2025, making it the third most commonly diagnosed cancer in the country. Non-melanoma skin cancers (NMSCs), including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), dwarf even that figure in sheer volume, with well over a million Medicare-paid treatment services recorded for NMSCs in 2022 alone. What makes the Australian skin cancer story particularly instructive for 2026 is the divergence between two powerful trends running simultaneously: incidence is rising in older age groups while rates among younger Australians — those who have grown up with the SunSmart and Slip-Slop-Slap public health campaigns — are stabilising or declining. Australia’s skin cancer burden is enormous, but it is also one of the most preventable cancer burdens in the world.
Key Facts About Skin Cancer in Australia 2026
FAST FACTS — Skin Cancer in Australia 2026
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
Lifetime risk of skin cancer (any type) : 2 in 3 Australians (~69%)
Share of all new cancer diagnoses : ~80%
Est. new melanoma cases (2025) : 17,443
Melanoma ranking (cancer diagnoses) : 3rd most common
Melanoma — 5-year survival rate : 94% (2017–2021)
Melanoma mortality rate (est. 2025) : 5.3 per 100,000
Est. melanoma deaths (2025) : ~1,455
Annual skin cancer deaths (all types) : 2,000+
Skin cancer — share of cancer health $ : Most expensive cancer type
UV radiation attributed melanoma cases : ~95%
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
| Key Fact | Statistic |
|---|---|
| Lifetime risk of any skin cancer (to age 70) | ~2 in 3 Australians (~69%) |
| Skin cancer share of all annual cancer diagnoses | ~80% |
| Estimated new melanoma diagnoses (2025) | 17,443 (10,187 males; 7,256 females) |
| Melanoma ranking among all cancers (2025) | 3rd most commonly diagnosed |
| 5-year melanoma survival rate (2017–2021) | 94% — highest ever recorded |
| Estimated melanoma deaths (2025) | ~1,455 |
| Age-standardised melanoma mortality rate (est. 2025) | 5.3 deaths per 100,000 persons |
| Annual deaths from all skin cancers | Over 2,000 |
| NMSC Medicare treatment services (2022) | 1,107,837 paid services |
| Total skin cancer health system cost (2019/20) | Over $1.72 billion AUD |
| Share of cancer health spending — NMSC alone | 8.1% |
| UV radiation as cause of melanoma (Australia) | ~95% of cases |
| UV radiation as cause of NMSC (Australia) | ~99% of cases |
| People living with melanoma at end of 2021 | 69,131 (diagnosed 2017–2021) |
| Australia’s global melanoma ranking | Highest age-standardised incidence rate in the world |
Source: Australian Institute of Health and Welfare (AIHW) — Cancer Data in Australia, 2025; Cancer Australia — Melanoma of the Skin Statistics, 2025; Cancer Council Australia — Skin Cancer Incidence and Mortality
The scale of Australia’s skin cancer problem becomes vivid when these figures are placed in context. The $1.72 billion AUD spent on skin cancer treatment in 2019/20 makes it the most expensive cancer to treat in the Australian health system — not despite skin cancer being “preventable,” but precisely because prevention has been imperfect and incidence is so high. Of that total, $1.463 billion was attributable to non-melanoma skin cancers (BCC and SCC) and $259 million to melanoma. The 1,107,837 Medicare-paid NMSC treatment services in 2022 translate to an average of more than 100 treatments per hour across Australia — a figure that illustrates just how embedded skin cancer treatment is in the everyday operation of Australia’s general practice and dermatology workforce. The 94% five-year survival rate for melanoma diagnosed between 2017 and 2021 is the highest ever recorded for that cancer in Australia, reflecting genuine progress in early detection and treatment — including the transformative impact of immunotherapy and targeted therapies introduced into clinical practice over the past decade.
The lifetime risk figures carry particular weight. The ~69% overall lifetime risk of skin cancer — 73% for men and 65% for women — means that skin cancer is not a niche health concern for a minority of Australians; it is the statistical norm. The risk to age 79 is approximately 60% overall (65% for men, 53% for women). These numbers put Australia in a category of its own globally: the International Agency for Research on Cancer (IARC) estimated that in 2020, Australia had the highest age-standardised melanoma incidence rate in the world at 36.6 per 100,000 people (standardised to the World Standard Population). Melanoma incidence rates in Australia and New Zealand are two to three times higher than those in Canada, the United States, and the United Kingdom — a gap that reflects geography, skin tone distribution, and decades of cultural sun exposure habits rather than any genetic predisposition unique to Australians.
Melanoma Incidence and Trends in Australia 2026
MELANOMA INCIDENCE — AGE-STANDARDISED RATE OVER TIME (per 100,000 persons)
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
1982 ████████████████████████████████ 30 per 100,000
2000 ████████████████████████████████████████ 54 per 100,000
2021 ████████████████████████████████████████████ 60 per 100,000
2025* ████████████████████████████████████████████▌ 63 per 100,000
*(estimated)
MALES vs FEMALES — estimated 2025
Males ████████████████████████████████████████████████████ 78 per 100,000
Females ████████████████████████████████ 50 per 100,000
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
| Melanoma Incidence Metric | Data |
|---|---|
| New melanoma cases (1982) | 3,561 (1,746 males; 1,815 females) |
| New melanoma cases (2021 — actual) | 15,034 (8,854 males; 6,170 females) |
| Estimated new melanoma cases (2025) | 17,443 (10,187 males; 7,256 females) |
| Age-standardised incidence rate (1982) | 30 cases per 100,000 persons |
| Age-standardised incidence rate (2000) | 54 cases per 100,000 persons |
| Age-standardised incidence rate (2021) | 60 cases per 100,000 persons |
| Age-standardised incidence rate (est. 2025) | 63 cases per 100,000 persons |
| Estimated rate — males (2025) | 78 per 100,000 |
| Estimated rate — females (2025) | 50 per 100,000 |
| Melanoma site — trunk (est. 2025) | 34% of all melanoma cases |
| Melanoma site — upper limbs incl. shoulder | 26% |
| Melanoma site — lower limbs incl. hip | 19% |
| Melanoma site — scalp and neck | 7.7% |
| Risk of melanoma diagnosis by age 85 (overall) | 1 in 19 (5.4%) |
| Risk by age 85 — males | 1 in 16 (6.4%) |
| Risk by age 85 — females | 1 in 24 (4.2%) |
| Mean age at diagnosis — males (2019) | 66.1 years |
| Mean age at diagnosis — females (2019) | 62.8 years |
Source: AIHW — Cancer Data in Australia, 2025; Cancer Australia — Melanoma of the Skin Statistics, 2025
The long-run incidence trend for melanoma in Australia is unmistakably upward over four decades: from 3,561 new cases in 1982 to an estimated 17,443 in 2025, a near five-fold increase in absolute case numbers over that period. The age-standardised rate — which adjusts for population ageing — has also climbed steadily, from 30 per 100,000 in 1982 to an estimated 63 per 100,000 in 2025. The gender gap is pronounced and persistent: men are estimated to develop melanoma at a rate of 78 per 100,000 compared to 50 per 100,000 for women in 2025, a disparity driven by both biological factors and behaviour — men are consistently less likely to apply sunscreen, wear sun-protective clothing, or seek early skin checks. The most common site for melanoma in 2025 is the trunk of the body at 34% of all cases, with notable differences by sex: the trunk accounts for 39% of male melanoma cases but only 26% of female cases, while the lower limbs account for 25% of female cases compared to just 14% for males.
There is, however, a genuinely positive signal buried within the long-term upward trend: rates among young Australians are declining. The risk of being diagnosed with melanoma by the age of 30 fell from 1 in 550 people in 1997 to 1 in 988 in 2019, and was estimated at 1 in 1,116 by 2023 — a more than halving of early-life risk over just 25 years. This decline is widely attributed to the SunSmart and Slip-Slop-Slap public health campaigns that began in the 1980s and have been embedded in Australian schools, workplaces, and community culture ever since. The cohorts who grew up with these programs are now showing measurably lower melanoma rates in their younger adult years — one of the clearest demonstrations in global public health of a prevention campaign translating into real, measurable reductions in cancer risk over generational timescales.
Melanoma Mortality and Survival Rates in Australia 2026
MELANOMA MORTALITY — AGE-STANDARDISED RATE (deaths per 100,000 persons)
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
1982 ████████████████████████████ 5.6 per 100,000
2013 ████████████████████████████████████████ 8.0 per 100,000 ← PEAK
2023 ██████████████████████████████ 5.9 per 100,000
2025* ███████████████████████████ 5.3 per 100,000
*(estimated)
5-YEAR SURVIVAL RATE FOR MELANOMA — SELECTED PERIODS
1997–2001 ████████████████████████████████████████████ ~91%
2017–2021 ██████████████████████████████████████████████ 94% ← HIGHEST EVER
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
| Melanoma Mortality & Survival Metric | Data |
|---|---|
| Melanoma deaths (1982) | 596 (380 males; 216 females) |
| Melanoma deaths (2013 — peak year) | 1,625 |
| Melanoma deaths (2023 — actual) | 1,527 |
| Estimated melanoma deaths (2025) | ~1,455 |
| Age-standardised mortality rate (1982) | 5.6 deaths per 100,000 |
| Age-standardised mortality rate (2013 — peak) | 8.0 deaths per 100,000 |
| Age-standardised mortality rate (2023) | 5.9 deaths per 100,000 |
| Estimated age-standardised mortality rate (2025) | 5.3 deaths per 100,000 |
| Estimated mortality rate — males (2025) | 7.9 per 100,000 |
| Estimated mortality rate — females (2025) | 3.1 per 100,000 |
| 5-year melanoma survival rate (1997–2001) | ~91% |
| 5-year melanoma survival rate (2017–2021) | 94% — highest ever recorded |
| 5-year survival — melanoma Stage I | 99% |
| 5-year survival — melanoma Stage IV | 26% |
| 5-year survival — Breslow thickness >4mm | 66% |
| Lifetime melanoma mortality risk (2013 peak) | 1 in 110 people |
| Lifetime melanoma mortality risk (estimated 2020) | 1 in 140 people |
| Melanoma ranking — cause of cancer death (2025) | 10th most common |
Source: AIHW — Cancer Data in Australia, 2025; Cancer Australia — Melanoma of the Skin Statistics, 2025
The melanoma mortality story in Australia is one of the most dramatic turnarounds in modern oncology. After decades of rising death rates, mortality peaked in 2013 at 8.0 deaths per 100,000 people — then began falling. By 2025, the estimated age-standardised mortality rate is 5.3 per 100,000, a reduction of 33.75% from the 2013 peak, and the estimated number of deaths has fallen from 1,625 in 2013 to approximately 1,455 in 2025 — despite a substantially larger population and significantly more diagnoses. This decoupling of incidence and mortality is the defining feature of Australia’s melanoma landscape in the mid-2020s: more people are being diagnosed, but a far higher proportion are surviving. The primary drivers are earlier detection through skin check programs and, crucially, the introduction of immunotherapy (checkpoint inhibitors) and BRAF-targeted therapies into routine clinical practice from around 2011 onwards — treatments that transformed the outlook for patients with advanced melanoma.
The survival data by stage at diagnosis underscores why early detection matters so profoundly. Stage I melanoma carries a 99% five-year survival rate — essentially, patients diagnosed this early live as long as those without melanoma. Stage IV melanoma, once almost universally fatal, now has a 26% five-year survival rate — still poor, but a transformation from the near-zero outcomes that prevailed before modern therapies. Breslow thickness — a measure of how deeply a melanoma has invaded at the time of diagnosis — is the key pathological predictor: tumours greater than 4mm thick carry a 66% five-year survival rate, compared to much higher rates for thin lesions. This is why skin check programs and GP-led early detection remain so critical: the difference between a melanoma found at 0.5mm depth and one found at 4mm+ is, statistically, the difference between life and death.
Non-Melanoma Skin Cancer (NMSC) in Australia 2026
NON-MELANOMA SKIN CANCER (NMSC) — KEY BURDEN INDICATORS
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
Medicare services for NMSC (2022)
████████████████████████████████████████ 1,107,837 services
Skin cancer health system cost (2019/20)
████████████████████████████████████████ $1.72 billion AUD total
↳ NMSC share $1.463 billion
↳ Melanoma share $259 million
NMSC mortality rate (2021, age-standardised)
Males ████████████████████████████████ 4.8 per 100,000
Females █████████████████ 1.7 per 100,000
Rate of NMSC treatments per hour in Australia
████████████████████████████████████████████ 100+ per hour
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
| NMSC Metric | Data |
|---|---|
| Most common form of skin cancer | Basal cell carcinoma (BCC) |
| Second most common NMSC | Squamous cell carcinoma (SCC) |
| Estimated Australians diagnosed with BCC (2008) | ~296,000 |
| Estimated Australians diagnosed with SCC (2008) | ~138,000 |
| NMSC Medicare treatment services (2022) | 1,107,837 paid services |
| Average NMSC treatments per hour (Australia) | 100+ |
| Total skin cancer health system cost (2019/20) | $1.72 billion AUD |
| NMSC share of skin cancer health system cost | $1.463 billion AUD |
| Melanoma share of skin cancer health system cost | $259 million AUD |
| NMSC share of all cancer health system spending | 8.1% |
| NMSC — most common cause of cancer hospitalisation | Yes |
| NMSC mortality rate — males (2021) | 4.8 deaths per 100,000 |
| NMSC mortality rate — females (2021) | 1.7 deaths per 100,000 |
| NMSC as cause of cancer death (2025) | Equal 18th most common |
| BCC/SCC treatments increase (1997–2010) | 86% increase (412,493 to 767,347 treatments) |
| UV radiation attribution — NMSC cases | ~99% of NMSC cases |
Source: Cancer Council Australia — Skin Cancer Incidence and Mortality; AIHW — Cancer Data in Australia, 2025; Department of Health Victoria — Non-Melanoma Skin Cancer Report
Non-melanoma skin cancers — primarily basal cell carcinoma and squamous cell carcinoma — are the dominant skin cancer burden in Australia by volume, health system cost, and treatment load, even though they receive considerably less public attention than melanoma. The 1,107,837 Medicare-paid NMSC treatment services in 2022 represent an extraordinary clinical workload, and the figure has been growing consistently for decades: there was an 86% increase in NMSC treatments between 1997 and 2010, from just over 412,000 to more than 767,000 annually. The majority of these treatments are delivered by general practitioners, making skin cancer management the single most common cancer-related activity in Australian general practice. AIHW and Cancer Council Australia data confirms that skin cancer is consistently among the top ten conditions managed in GP-patient encounters nationally, appearing in annual surveys as the most frequently managed cancer diagnosis across every year they were conducted.
The economic figures are stark. NMSC alone costs the Australian health system $1.463 billion annually — more than six times the cost attributable to melanoma ($259 million). This is despite the fact that NMSCs are generally not life-threatening when treated promptly; the cost reflects sheer volume of cases requiring surgical excision, curettage, cryotherapy, and pathological assessment. The 8.1% share of all cancer health spending attributable to NMSCs reinforces that these cancers, while not often fatal, impose an enormous burden on healthcare infrastructure, GPs, dermatologists, pathologists, and the Medicare system. NMSC mortality rates remain relatively low — 4.8 per 100,000 for males and 1.7 per 100,000 for females in 2021 — but their aggregate impact on the health system is larger than most Australians appreciate.
Risk Factors for Skin Cancer in Australia 2026
KEY RISK FACTOR CONTRIBUTORS — Skin Cancer in Australia
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
UV radiation — % of melanoma cases attributed
████████████████████████████████████████████████ ~95%
UV radiation — % of NMSC cases attributed
████████████████████████████████████████████████▌ ~99%
Occupational UV exposure melanomas per year (est.)
████ ~200 melanomas
Occupational UV exposure NMSC per year (est.)
████████████████████████████████ ~34,000 KCs
Outdoor workers UV dose vs indoor workers
████████████████████████████████████████████████ 5–10x higher
Australians NOT using adequate sun protection (2024)
████████████████████████ ~50%
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
| Risk Factor | Data |
|---|---|
| UV radiation — melanoma cases attributed | ~95% of all melanoma cases in Australia |
| UV radiation — NMSC cases attributed | ~99% of NMSC cases in Australia |
| UV classified as | Group 1 carcinogen (IARC, 2012) |
| Outdoor workers’ UV dose vs indoor workers | 5 to 10 times higher |
| Occupational exposure melanomas (est. annually) | ~200 melanomas |
| Occupational exposure NMSCs (est. annually) | ~34,000 keratinocyte cancers |
| Intense sun exposure in first 10 years of life | Nearly doubles lifetime melanoma risk |
| Sunburn in childhood relative risk for melanoma | Relative risk = 2 |
| BCC/SCC rates — high UV latitudes vs low | ~3 times higher in latitudes closer to equator |
| Solarium use before age 30 | Classified Group 1 carcinogen; increases melanoma risk |
| Commercial solarium ban effective | 1 January 2015 (all states except NT and WA) |
| Australians not using adequate sun protection (2024) | ~50% (Cancer Council survey) |
| Australia’s UV levels | Among highest in the world year-round |
| Queensland historical melanoma rate | ~64.3 per 100,000 vs national ~48.7 |
| Northern Territory historical melanoma rate | Lowest nationally (~30.5 per 100,000) |
Source: Cancer Australia — UV Radiation Position Statement; Cancer Council Australia — Link Between UV and Skin Cancer; Cancer Council — Sun Protection Survey 2024; AIHW — Cancer Data in Australia, 2025
UV radiation is not a contributing factor to Australian skin cancer — it is the defining, overwhelming cause. The attribution figures — ~95% of melanomas and ~99% of NMSCs caused by UV exposure — mean that skin cancer in Australia is, in the most meaningful sense, an environmentally induced disease. The Group 1 carcinogen classification from IARC confirms that the causal link between UV radiation and skin cancer is beyond scientific dispute. What makes the Australian context particularly acute is the combination of high-UV geography and a population that, for much of the 20th century, equated tanned skin with good health. The “Slip-Slop-Slap” campaign that launched in 1981 began changing that cultural norm — but decades of deeply ingrained sun exposure habits continue to manifest as skin cancers in older Australians today. Cancer Council Australia’s 2024 survey data found that approximately 50% of Australians are still not using adequate sun protection when outdoors — a figure that underscores how much work remains in behavioural change.
The occupational exposure dimension is a significant and sometimes overlooked element of Australia’s skin cancer burden. Workers in industries like construction, agriculture, landscaping, and outdoor recreation are exposed to five to ten times more UV radiation than those working indoors. It is estimated that approximately 200 melanomas and 34,000 keratinocyte cancers (BCC and SCC) per year in Australia are directly attributable to occupational UV exposure — a workplace health issue that remains underaddressed relative to its scale. The geographic gradient within Australia is also stark: in high-UV latitudes, BCC and SCC rates are approximately three times higher than in lower-latitude areas, which explains why Queensland has historically recorded the highest melanoma incidence rate nationally (approximately 64.3 per 100,000) while the Northern Territory, with its higher proportion of darker-skinned First Nations populations who have greater natural UV protection, records among the lowest.
Melanoma Among Young Australians and Demographic Data 2026
MELANOMA IN YOUNG AUSTRALIANS — KEY TRENDS
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
Risk of melanoma by age 30 — TREND (persons)
1997 ████████████████████████████ 1 in 550 people
2019 ██████████████ 1 in 988 people
2023* █████████████ 1 in 1,116 people ← Continued decline
Melanoma is the #1 cancer in Australians aged 15–29
Share of all cancers — 15 to 29 age group: 15%
Proportion of melanoma patients aged under 40: 7.9%
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━
| Demographic / Age Metric | Data |
|---|---|
| Most common cancer in Australians aged 15–29 | Melanoma |
| Melanoma share of all cancers — aged 15–29 | 15% |
| Proportion of all melanoma cases — aged under 40 | 7.9% |
| Risk of melanoma diagnosis by age 30 (1997) | 1 in 550 people |
| Risk of melanoma diagnosis by age 30 (2019) | 1 in 988 people |
| Risk of melanoma diagnosis by age 30 (est. 2023) | 1 in 1,116 people |
| Age group with highest melanoma incidence | 85–89 years |
| Melanoma incidence rate increase with age | Continues rising to age 80–84 peak |
| Australia-born melanoma incidence rate | 51 per 100,000 |
| Overseas-born melanoma incidence rate (2006–2020) | 17 per 100,000 |
| Mean age at melanoma diagnosis — males | 66.1 years (2019) |
| Mean age at melanoma diagnosis — females | 62.8 years (2019) |
| NMSC excision rate trend — under 45s (2000–2011) | Declined significantly |
| SunSmart-era cohort effect | Measurable reduction in under-60 melanoma rates |
Source: Cancer Council Australia — Skin Cancer Incidence and Mortality; AIHW — Cancer Data in Australia, 2025; Cancer Australia — Melanoma Statistics
Melanoma holds the grim distinction of being the most commonly diagnosed cancer among young Australians aged 15 to 29, accounting for 15% of all cancer diagnoses in this age group — but the directional trend is encouraging. The halving of early-life melanoma risk over 25 years (from 1 in 550 by age 30 in 1997 to an estimated 1 in 1,116 by 2023) is one of the most significant public health achievements in Australian cancer history, and it can be attributed directly to the cumulative behavioural impact of decades of sun protection education in schools and communities. The SunSmart cohorts — those who grew up in the 1980s, 1990s, and 2000s with sun protection messaging embedded in their childhood — are now showing the fruits of that investment in measurably lower melanoma rates in their younger adult years. Victorian Cancer Registry data shows melanoma rates are “stabilising or declining” in all age groups under 60 years, a finding consistent with the broader national trend.
The contrast between Australia-born and overseas-born Australians is illuminating. Australia-born Australians develop melanoma at a rate of approximately 51 per 100,000, while overseas-born Australians develop it at just 17 per 100,000 — roughly one-third the rate. This disparity reflects the interaction of UV exposure patterns (overseas-born Australians often spent formative years in lower-UV countries), skin phototype (overseas-born populations frequently have darker skin with higher natural UV protection), and cultural behaviour around sun exposure. This demographic difference does not reduce the overall burden on the Australian health system, but it reinforces that the skin cancer epidemic in Australia is deeply linked to fair skin, cumulative UV exposure, and the behavioural norms of populations whose ancestors evolved in low-UV environments being transplanted into one of the highest-UV environments on the planet.
Disclaimer: The data research report we present here is based on information found from various sources. We are not liable for any financial loss, errors, or damages of any kind that may result from the use of the information herein. We acknowledge that though we try to report accurately, we cannot verify the absolute facts of everything that has been represented.
